Drug Type Bispecific antibody |
Synonyms KM257, KM257/252, XZP-KM257 |
Target |
Action antagonists |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 1 | China | 12 May 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Apr 2022 | |
Bile Duct Neoplasms | Phase 1 | China | 30 Jan 2022 | |
Bladder Cancer | Phase 1 | China | 30 Jan 2022 | |
Breast Cancer | Phase 1 | China | 30 Jan 2022 | |
Stomach Cancer | Phase 1 | China | 30 Jan 2022 |